NM Merchantiles Limited has announced a significant acquisition of equity shares in IOL Chemicals and Pharmaceuticals Limited through a regulatory disclosure filed under SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The acquisition was completed through a merger transaction that transferred substantial shareholding from Vasudeva Commercials Limited.

Acquisition Details

The transaction involved the acquisition of 1,17,41,100 equity shares of IOL Chemicals and Pharmaceuticals Limited, representing a 4.00% increase in both total share capital and voting rights. The shares were transferred under a merger scheme approved by the Hon'ble Regional Director (NR) New Delhi through Order Numbers RDNR/233/AC1499296/2026/14531 and RDNR/233/AC1499296/2026/14530 dated 12.02.2026.

Merger Transaction Structure

The acquisition was executed through the merger of Vasudeva Commercials Limited with NM Merchantiles Limited. The shares of IOL Chemicals and Pharmaceuticals Limited previously held by Vasudeva Commercials were transferred to NM Merchantiles' account as part of this corporate restructuring. The effective date of share transfer was 05th March 2026.

Company Information

Regulatory Compliance

The disclosure was made in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. NM Merchantiles Limited, formerly known as NM Merchantiles Private Limited, filed the necessary documentation with both the National Stock Exchange and BSE Limited, where IOL Chemicals and Pharmaceuticals Limited shares are listed.

The transaction maintains the total equity share capital of IOL Chemicals and Pharmaceuticals Limited at Rs. 58,70,55,020, comprising 29,35,27,510 equity shares of Rs. 2 each. The acquisition strengthens NM Merchantiles' position as a promoter group entity in the target company, with no changes to the overall share capital structure of IOL Chemicals and Pharmaceuticals Limited.

IOL Chemicals & Pharmaceuticals has secured an important regulatory milestone with the European Directorate for the Quality of Medicines & Health Care (EDQM) granting a Certificate of Suitability (CEP) for its API product Metformin Hydrochloride Process-II. This achievement expands the company's regulatory portfolio for this critical antidiabetic medication.

Regulatory Certification Details

The EDQM certification represents a significant regulatory approval for IOL Chemicals & Pharmaceuticals' manufacturing processes. The company disclosed that this new CEP comes in addition to an existing valid certificate already held for Metformin Hydrochloride, indicating the company now has multiple approved processes for manufacturing this important pharmaceutical ingredient.

Product Significance

Metformin Hydrochloride serves as a crucial antidiabetic drug used to manage high blood sugar levels in diabetes patients. The availability of multiple certified manufacturing processes for this API demonstrates IOL Chemicals & Pharmaceuticals' commitment to ensuring reliable supply and manufacturing flexibility for this essential medication.

Regulatory Compliance

The company announced this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure ensures transparency with stakeholders and regulatory authorities regarding this significant regulatory achievement.

Strategic Impact

This additional EDQM certification strengthens IOL Chemicals & Pharmaceuticals' position in the pharmaceutical API market, particularly for diabetes management medications. Having multiple approved processes for Metformin Hydrochloride production provides the company with enhanced manufacturing capabilities and regulatory compliance across European markets.